Eczema: Barrier-First Care — and When It's Time for Biologics
Eczema care has quietly split into two worlds: the ceramide-and-occlusion basics that manage most cases, and a new class of drugs rewriting what's possible for severe disease. Knowing which world you're in changes the whole plan.
Read the preview
From the DermApproved blog, in Skin Concerns: eczema — and a quiet split in how it's treated that most people never hear about. Here's the thing. Eczema isn't one broken thing, it's two, feeding each other in a loop — and that changes what actually fixes it. For most people, the answer is almost boringly simple, and it lives on a drugstore shelf. But there's a second world entirely: a new tier of drugs that has rewritten the ceiling for severe, won't-quit disease — the kind topicals never touched. The catch? Knowing which world you're in, because using the wrong tier is either useless or overkill. There's also a widespread fear that's quietly making things worse, not better. Which tier is yours, and when is it genuinely time to escalate? We map both — at dermapproved.com/blog.
Two broken things, not one
The single most useful thing to understand about eczema is that it isn't one malfunction — it's two, feeding each other in a loop. On one side is a leaky skin barrier. In many people with atopic dermatitis, mutations or reduced expression of filaggrin — a protein that helps knit the outer skin layer into a tight, water-holding wall — leave the barrier porous. Water escapes outward (measured as elevated transepidermal water loss), and irritants, allergens, and microbes get in more easily. A recent comprehensive review of atopic dermatitis describes exactly this defect: decreased epidermal differentiation proteins, disrupted tight junctions, and lower levels of the very long-chain fatty acids and ceramides that normally seal the skin.
On the other side is an over-primed immune system, skewed toward a 'type 2' (Th2) inflammatory response with signaling molecules IL-4 and IL-13 at the center. Those cytokines don't just cause itch and redness — they actively suppress the skin's production of barrier lipids and filaggrin, which worsens the leak, which lets in more triggers, which fuels more inflammation. That vicious circle is why eczema is chronic and relapsing, and why the smartest treatment strategy attacks both fronts: rebuild the wall from the outside, and, when needed, turn down the immune signal from within.
The unglamorous foundation that actually works
Before anything fancier, the barrier basics carry most cases — and they're boring on purpose. The core move is moisturizing generously and often with a formula built to patch a leaky barrier: ceramides to replace the missing lipids, plus humectants and an occlusive layer to slow water loss. A thick, fragrance-free classic like CeraVe Moisturizing Cream pairs three ceramides with cholesterol and petrolatum, hitting both the lipid-replacement and occlusion jobs at once. For sensitive, reactive skin that reacts to seemingly everything, a stripped-down formula such as Vanicream Enhanced Moisturizer — free of fragrance, dyes, and common sensitizers — is a safe default, and the [ingredient-decoder] helps you screen a new product for the fragrance and botanical extracts that commonly provoke eczematous skin.
Cleansing matters as much as moisturizing. Harsh, high-pH, sulfate-heavy washes strip the already-depleted barrier; a gentle, non-foaming or low-foam cleanser like La Roche-Posay Toleriane Caring Wash cleans without scouring. The technique that ties it together is 'soak and seal': a short, lukewarm (not hot) bath or shower, then applying moisturizer to still-damp skin within a couple of minutes to trap the water that just went in. Do this daily, not just when flaring. For hands and other hot spots, an oatmeal-and-ceramide repair cream such as SkinFix Eczema+ Hand Repair Cream targets the areas that crack and re-flare first. None of this is exciting, but consistency here is what keeps most eczema from ever needing the heavier artillery.
Using the flare toolkit correctly (and getting over steroid fear)
Moisturizer manages the baseline; it doesn't put out an active fire. For flares — the hot, itchy, inflamed patches — the frontline anti-inflammatories are topical corticosteroids, and the biggest problem in practice is that people are too afraid of them, not too cavalier. Used correctly (an appropriate potency for the body site, applied to active flares for a defined stretch, then tapered), short courses of topical steroids are effective and safe. The genuine harms — skin thinning, stretch marks — come from high-potency steroids used continuously for long periods on delicate areas, not from treating a flare properly. Under-treating, by contrast, leaves inflammation smoldering and the itch-scratch cycle running.
For sensitive zones like the face and eyelids, or for keeping flares at bay without ongoing steroids, non-steroidal options fill the gap: topical calcineurin inhibitors (tacrolimus, pimecrolimus) and the PDE4 inhibitor crisaborole calm inflammation through different mechanisms and don't thin skin, making them well suited to maintenance and delicate areas. A 'proactive' approach — dabbing a topical anti-inflammatory on the spots that habitually flare, a couple of times a week even when they look calm — can head off full flares before they start. Tracking what sets yours off (a flare-diary of triggers, weather, stress, and products) turns vague frustration into a pattern you can actually act on, and it makes any eventual dermatologist visit far more productive.
When topicals aren't enough: the biologic tier
Here is where eczema care genuinely bifurcated. For decades, if creams and short steroid courses failed, the options were blunt: broad oral immunosuppressants like cyclosporine or methotrexate, or phototherapy — helpful but with real trade-offs. That changed with drugs that target the specific immune signals behind atopic dermatitis. Dupilumab, a monoclonal antibody that blocks IL-4 and IL-13 signaling — the exact cytokines at the heart of the Th2 loop — brought many people with moderate-to-severe disease to clear or near-clear skin for the first time, with a safety profile mild enough that it doesn't require the lab monitoring older immunosuppressants do.
The second wave is the JAK inhibitors — oral drugs like upadacitinib and abrocitinib, plus topical ruxolitinib — which block the intracellular relay (the Janus kinase–STAT pathway) that multiple inflammatory cytokines share. They tend to work fast and control itch impressively, with the trade-off of a boxed warning and a need for monitoring, which is why they're typically reserved for disease that's failed or can't use other systemics. What's striking is that these drugs don't just mask symptoms: a systematic review of IL-4/13 inhibitors and JAK inhibitors found they measurably restore barrier function — lowering transepidermal water loss, raising stratum corneum hydration, and improving ceramide and filaggrin markers — which closes the loop neatly. Quiet the immune signal, and the barrier starts rebuilding itself.
Which world are you in?
The practical question isn't 'what's the best eczema treatment' — it's 'which tier does my eczema actually need,' because the answer reshapes everything. Most eczema is mild to moderate and lives comfortably in the first world: barrier-first basics plus correct flare management. If your skin is controlled with diligent moisturizing and the occasional steroid course, you do not need a biologic, and reaching for one would be using a cannon on a candle. The honest caveat for this tier is that the basics only work if you actually do them daily — the failure mode is inconsistency, not a lack of stronger drugs.
You're in the second world if your eczema is moderate-to-severe and persistent: widespread, sleep-wrecking, itch-dominated disease that keeps flaring despite genuine, consistent topical effort. That's the signal to escalate — not to a stronger scrub or a pricier cream, but to a clinician who can assess whether dupilumab or a JAK inhibitor is warranted. Grading your own severity honestly (an eczema-severity self-check on how much body surface is involved, how bad the itch is, and how much it disrupts sleep) helps you walk in with a clear picture rather than downplaying it, which people with lifelong eczema tend to do reflexively. The two worlds aren't a hierarchy of effort or willpower — they're different diseases in the same family, and matching the tool to the tier is the whole point.
Products mentioned
Independently reviewed and scored — the real products behind this piece.
References
- Restoration of Skin Barrier Abnormalities with IL4/13 Inhibitors and Jak Inhibitors in Atopic Dermatitis: A Systematic Review — International Journal of Molecular Sciences, 2024
- Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights — Inflammopharmacology, 2025
- JAK Inhibitors in the Treatment of Atopic Dermatitis — Journal of Clinical Medicine, 2023
Every cited link is verified to resolve to the paper named. Where a source could not be independently confirmed, it is listed without a link rather than pointing you somewhere wrong.
Frequently asked
What's the single most important step in an eczema routine?
Generous, frequent moisturizing with a ceramide-rich, fragrance-free formula, ideally applied to damp skin right after a lukewarm bath or shower — the 'soak and seal' method. Because eczema is fundamentally a leaky-barrier problem, replacing lipids and trapping water does more day-to-day than any single treatment. Do it daily, not just when your skin is flaring.
Are topical steroids safe to use on eczema?
Used correctly — an appropriate strength for the body area, applied to active flares for a defined period, then tapered — topical steroids are safe and effective. Thinning and stretch marks come from strong steroids used continuously on delicate skin for long stretches, not from treating flares properly. In practice, under-treating out of fear causes more trouble than short, correct courses.
When should I consider dupilumab or a JAK inhibitor for eczema?
When eczema is moderate-to-severe and keeps flaring despite consistent barrier care and correct topical treatment — widespread, itchy, sleep-disrupting disease. That's the point to see a clinician about systemic options. Dupilumab targets the IL-4/IL-13 pathway with a mild safety profile; oral JAK inhibitors work fast on itch but carry warnings and require monitoring, so they're reserved for harder cases.
Can eczema actually be cured?
No — atopic dermatitis is a chronic, relapsing condition rooted in your barrier genetics and immune tendencies, so the goal is long-term control rather than a permanent cure. That said, control has improved dramatically: most cases stay quiet with barrier basics, and severe disease that was once unmanageable can now reach clear or near-clear skin with biologics.
Do biologics fix the skin barrier or just calm the itch?
Both. A systematic review of IL-4/13 inhibitors and JAK inhibitors found they measurably improve barrier markers — reducing transepidermal water loss, raising stratum corneum hydration, and improving ceramide and filaggrin levels — not just reducing visible inflammation. Quieting the immune signal lets the barrier begin rebuilding, which is why the effect tends to be self-reinforcing.